Reason for request
Extension of indication
Clinical Benefit
| Substantial |
The actual benefit of CERUBIDINE 20 mg is substantial, as part of a combination chemotherapy regimen, in the treatment of acute lymphoblastic leukaemia and acute myeloblastic leukaemia in children. |
Clinical Added Value
| no clinical added value |
CERUBIDINE 20 mg does not provide any improvement in actual benefit (level V, non-existent) in the treatment of acute lymphoblastic and myeloblastic leukaemia in children. |
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
jPuM5z9tKB6nLjjr
